TAF7

TAF7 is a TFIID subunit that functions as a checkpoint regulator gating the transition from preinitiation complex (PIC) assembly to productive transcription elongation (PMID:18391197). Within TFIID, TAF7 binds the RAP74-binding domain of TAF1 (TAFII250) and inhibits its acetyltransferase activity, holding the complex in a repressed state (PMID:11592977); this restraint is relieved when TAF1 phosphorylates TAF7 at serine-264, disrupting the TAF1/TAF7 interaction, activating TAF1 HAT activity and promoting histone H3 acetylation and transcription at cyclin D1 and cyclin A promoters (PMID:22711989). Structural work shows TAF7 and TAF1 co-fold into a compact, inter-digitated heterodimer bearing a TAF1 winged-helix DNA-binding domain and a conserved pocket that reads trimethylated histone H3K27, coupling epigenetic mark recognition to PIC regulation (PMID:25412659, PMID:24927529). Upon initiation, TAF7 is released from TFIID and inhibits the RNA Pol II CTD kinase activities of TFIIH and P-TEFb, co-elongating with Pol II downstream of the promoter (PMID:18391197), with a competitive folding-upon-binding switch on the MED26 N-terminal domain marking the initiation-to-elongation handoff (PMID:28893534). TAF7 also inhibits the acetyltransferase activity of the coactivator CIITA to repress MHC gene transcription (PMID:20937824), and is essential for global transcription, proliferation, and T-cell development in vivo (PMID:22411629). TAF7 abundance is controlled post-translationally: TGF-β-induced TRIM26 ubiquitylates TAF7 for proteasomal degradation to enforce proliferative arrest (PMID:29203640), while SETD7 methylation deubiquitinates and stabilizes TAF7 to enhance its activity at the cyclin A2 promoter (PMID:38904013). Beyond transcription, TAF7 acts as a cytoplasmic RNA chaperone, binding CUG-motif-containing 3' UTRs and exporting target mRNAs to polysomes through an exportin 1 (CRM1)-dependent nuclear export signal (PMID:34890234).

1. 1997 Low

   An early question was whether TAF7 contacts sequence-specific factors beyond the basal machinery; YY1 was found to bind TAF7, hinting at a role in repression or initiation rather than transactivation.

   Evidence Co-immunoprecipitation and deletion mutagenesis with reporter assays

   PMID:8999850

   Open questions at the time

   • Single co-IP with no functional follow-up specific to the TAF7 interaction
   • Domain mapping of the binding interface incomplete
2. 1999 Medium

   To test whether TAF7 links TFIID to ligand-activated transcription, it was shown to bind nuclear receptor ligand-binding domains independent of ligand and correlate with enhanced activation.

   Evidence Co-IP in COS cells, deletion mapping, reporter assays

   PMID:10409738

   Open questions at the time

   • Functional link is correlative
   • Single lab, no in vivo validation
3. 2001 High

   The first defined biochemical activity of TAF7 was established: it binds the TAF1 RAP74-binding domain and inhibits TAF1 acetyltransferase activity, repressing TAF1-dependent transcription.

   Evidence Yeast two-hybrid, co-IP, in vitro acetyltransferase and transcription assays

   PMID:11592977

   Open questions at the time

   • How inhibition is relieved was not defined
   • Structural basis of the interaction unknown at this stage
4. 2003 Medium

   TAF7 interactions with sequence-specific activators were extended to c-Jun, indicating TAF7 can engage DNA-bound phosphorylated transcription factors to modulate their activity.

   Evidence GST pulldown, co-IP, reporter assays in HEK293/COS cells

   PMID:12676957

   Open questions at the time

   • Mechanism of transactivation enhancement undefined
   • No endogenous-gene validation
5. 2003 Medium

   A germ-cell-specific paralogue (TAF7L) was shown to associate with TBP/TAF1 and replace TAF7 during spermatogenesis, establishing tissue-specific TFIID remodeling around the TAF7 slot.

   Evidence Co-IP, immunofluorescence, staged western blotting

   PMID:12665565

   Open questions at the time

   • Functional consequences of the swap not directly tested
   • Concerns paralogue rather than TAF7 itself
6. 2008 High

   The checkpoint model emerged: TAF7 is released from TFIID at initiation and then inhibits the CTD kinases of TFIIH and P-TEFb, gating the step after PIC assembly while co-elongating with Pol II.

   Evidence Co-IP, in vitro CTD kinase and transcription assays, ChIP co-elongation in vivo

   PMID:18391197

   Open questions at the time

   • Trigger for TAF7 release from TFIID not defined
   • Structural basis of kinase inhibition unknown
7. 2010 High

   TAF7's inhibitory acetyltransferase regulation was generalized beyond TAF1: it binds and inhibits CIITA AT activity to repress TAF1-independent MHC transcription.

   Evidence Co-IP, in vitro acetyltransferase assay, siRNA with expression analysis

   PMID:20937824

   Open questions at the time

   • Structural mode of CIITA inhibition unknown
   • Physiological contexts not mapped
8. 2012 High

   The relief mechanism for TAF1 inhibition was defined: TAF1 phosphorylates TAF7 at S264, disrupting the heterodimer, activating TAF1 HAT and driving cyclin promoter transcription.

   Evidence Phospho-mapping, S264A/S264D mutants, ChIP for H3 acetylation, knockdown

   PMID:22711989

   Open questions at the time

   • Upstream signals controlling TAF1 kinase activity unclear
   • Generality beyond cyclin promoters not established
9. 2012 High

   Genetic essentiality was established: germline TAF7 loss is embryonic lethal and conditional deletion abolishes transcription and proliferation, including immature thymocyte and T-cell expansion.

   Evidence Conditional knockout mouse, MEF profiling, flow cytometry, T-cell activation assays

   PMID:22411629

   Open questions at the time

   • Distinguishes proliferation-dependent from -independent programs but mechanism of selectivity unresolved
   • Cell-type-specific target genes not catalogued
10. 2014 High

    Crystal structures of the TAF1-TAF7 core revealed an inter-digitated heterodimer with a DNA-binding winged-helix domain and an H3K27me3-reading pocket, providing the structural basis for chromatin-coupled PIC regulation.

    Evidence X-ray crystallography (human and yeast complexes), DNA/histone-peptide binding, mutagenesis, ts13 rescue

    PMID:24927529 PMID:25412659

    Open questions at the time

    • How H3K27me3 reading feeds into transcriptional output in vivo not shown
    • Conformational changes during TAF7 release not captured
11. 2017 High

    The initiation-to-elongation handoff was given a structural switch: TAF7 folds upon binding the MED26 NTD groove in competition with EAF1, coupling Mediator engagement to transition control.

    Evidence NMR structure, chemical-shift mapping, ITC (Kd ~10 µM), alanine mutagenesis

    PMID:28893534

    Open questions at the time

    • In vivo relevance of the TAF7/EAF1 competition not demonstrated
    • Temporal ordering relative to CTD-kinase inhibition unresolved
12. 2018 Medium

    Post-translational control of TAF7 abundance was uncovered: TGF-β-induced TRIM26 ubiquitylates TAF7 for degradation to enforce proliferative arrest, antagonized by MYC.

    Evidence Co-IP, ubiquitylation assay, proteasome rescue, siRNA, MYC amplification analysis

    PMID:29203640

    Open questions at the time

    • Direct ubiquitylation sites on TAF7 not mapped
    • Single lab
13. 2018 Medium

    TAF7 phosphorylation was tied to both TFIID interaction and proteasomal stability, and TAF7 was shown to sustain heat-shock gene expression by enhancing Pol II at gene bodies during prolonged transcription.

    Evidence ChIP, RT-qPCR, western blotting, phospho-analysis, proteasome inhibition

    PMID:30028080

    Open questions at the time

    • Specific phospho-residues governing stability not defined
    • Mechanism of Pol II body enrichment unresolved
14. 2021 High

    A non-transcriptional function was established: TAF7 binds CUG-motif 3' UTR RNAs and exports them to polysomes via an exportin 1-dependent NES, acting as a cytoplasmic RNA chaperone.

    Evidence RNA-IP, CLIP-seq, fractionation, polysome profiling, leptomycin B, NES/RNA-motif mutagenesis

    PMID:34890234

    Open questions at the time

    • Relationship between RNA-export and TFIID roles not integrated
    • Structural basis of RNA recognition unknown
15. 2024 Medium

    A stabilizing modification was added to the regulatory repertoire: SETD7 methylates TAF7 at K5/K300, causing deubiquitination, stabilization, and increased activity at the cyclin A2 promoter.

    Evidence In vitro methylation, K5/K300 mutagenesis, ubiquitination assay, ChIP, reporter assays

    PMID:38904013

    Open questions at the time

    • Crosstalk with TRIM26-mediated degradation not tested
    • Single lab
16. 2025 Medium

    TAF7 was linked to disease physiology: it directly activates SAA1 transcription to drive TNBC cell invasion and lung metastasis.

    Evidence ChIP, knockdown/overexpression, reporter, invasion/migration assays, xenograft metastasis model

    PMID:40083715

    Open questions at the time

    • Whether this reflects TFIID or RNA-chaperone activity unclear
    • Single lab

• How TAF7's distinct activities — TFIID-resident HAT inhibition, CTD-kinase gating, chromatin-mark reading, and cytoplasmic mRNA export — are coordinated within one cell and which signals partition TAF7 between them remains unresolved.
• No unified model linking nuclear transcriptional and cytoplasmic RNA-export functions
• Signal-dependent switching between activities uncharacterized